Regulatory Story
Go to market news section View chart   Print
Company Shire plc
TIDM SHP
Headline

Transaction in Own Shares

Released 07:00 25-Sep-2013
Number 32255-4404

Transaction in Own Shares

Transaction in Own Shares

September 25, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")
announces that, in accordance with the authority granted by shareholders at the
Company's Annual General Meeting on April 30, 2013, it purchased 24,699 of its
ordinary shares of 5 pence each ("Ordinary Shares") on September 24, 2013
through both direct purchases of Ordinary Shares, and through the purchase of
Ordinary Shares underlying ADRs. The highest and lowest price paid for the
directly acquired Ordinary Shares was 2495.00 pence per share and 2446.00 pence
per share respectively, and for those Ordinary Shares acquired though the
purchase of ADRs was 4025.67 cents per share and 3985.00 cents per share
respectively.

The purchased shares will be held as treasury shares. Following the above
purchase, the Company holds 9,747,901 Ordinary Shares as treasury shares and
has 553,152,329 Ordinary Shares in issue (excluding treasury shares).

The purchases were made by an independent third party which makes its trading
decisions independently of, and uninfluenced by, the Company. The independence
of the third party enables the Company to continue to purchase Ordinary Shares
(including Ordinary Shares underlying ADRs) during close periods and other
prohibited periods, should they arise. The third party has been appointed by
the Company to make purchases to December 31, 2013.

For further information please contact:

Investor Relations                                                             
                                                                               
Eric Rojas                              erojas@shire.com     +1 781 482 0999   
                                                                               
Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157   

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas.

www.shire.com

                                                                              
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release                                     
                                                  
www.shire.com

Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Transaction in Own Shares - RNS